Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia
Rituximab is an anti-CD20 monoclonal antibody that has been used to treat several complications of systemic lupus erythematosus (SLE) including nephritis, cerebritis, and hematological disorders. Neutropenia is among the adverse events associated with rituximab; this usually occurs several weeks aft...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Case Reports in Rheumatology |
Online Access: | http://dx.doi.org/10.1155/2015/616787 |
id |
doaj-d71e42021d774f18b517c161ccdaed32 |
---|---|
record_format |
Article |
spelling |
doaj-d71e42021d774f18b517c161ccdaed322020-11-24T22:54:21ZengHindawi LimitedCase Reports in Rheumatology2090-68892090-68972015-01-01201510.1155/2015/616787616787Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic AnemiaMariangelí Arroyo-Ávila0Ruth M. Fred-Jiménez1Luis M. Vilá2Division of Rheumatology, Department of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USADivision of Rheumatology, Department of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USADivision of Rheumatology, Department of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USARituximab is an anti-CD20 monoclonal antibody that has been used to treat several complications of systemic lupus erythematosus (SLE) including nephritis, cerebritis, and hematological disorders. Neutropenia is among the adverse events associated with rituximab; this usually occurs several weeks after therapy. However, early-onset neutropenia has been reported only in a few cases. Herein, we describe a 36-year-old Hispanic SLE woman who developed severe early-onset neutropenia (0.3 × 109/L) after the second weekly rituximab infusion (375 mg/m2 weekly × 4) given for nephritis and hemolytic anemia. She also had early-onset thrombocytopenia after rituximab therapy. Both hematological disorders resolved 12 days after the fourth and final dose. This case, together with few others, suggests that early-onset neutropenia may occur during rituximab therapy. Even though rituximab-induced neutropenia seems to be transient, it may predispose SLE patients to severe complications such as infections.http://dx.doi.org/10.1155/2015/616787 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mariangelí Arroyo-Ávila Ruth M. Fred-Jiménez Luis M. Vilá |
spellingShingle |
Mariangelí Arroyo-Ávila Ruth M. Fred-Jiménez Luis M. Vilá Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia Case Reports in Rheumatology |
author_facet |
Mariangelí Arroyo-Ávila Ruth M. Fred-Jiménez Luis M. Vilá |
author_sort |
Mariangelí Arroyo-Ávila |
title |
Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia |
title_short |
Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia |
title_full |
Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia |
title_fullStr |
Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia |
title_full_unstemmed |
Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia |
title_sort |
early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia |
publisher |
Hindawi Limited |
series |
Case Reports in Rheumatology |
issn |
2090-6889 2090-6897 |
publishDate |
2015-01-01 |
description |
Rituximab is an anti-CD20 monoclonal antibody that has been used to treat several complications of systemic lupus erythematosus (SLE) including nephritis, cerebritis, and hematological disorders. Neutropenia is among the adverse events associated with rituximab; this usually occurs several weeks after therapy. However, early-onset neutropenia has been reported only in a few cases. Herein, we describe a 36-year-old Hispanic SLE woman who developed severe early-onset neutropenia (0.3 × 109/L) after the second weekly rituximab infusion (375 mg/m2 weekly × 4) given for nephritis and hemolytic anemia. She also had early-onset thrombocytopenia after rituximab therapy. Both hematological disorders resolved 12 days after the fourth and final dose. This case, together with few others, suggests that early-onset neutropenia may occur during rituximab therapy. Even though rituximab-induced neutropenia seems to be transient, it may predispose SLE patients to severe complications such as infections. |
url |
http://dx.doi.org/10.1155/2015/616787 |
work_keys_str_mv |
AT mariangeliarroyoavila earlyonsetneutropeniainducedbyrituximabinapatientwithlupusnephritisandhemolyticanemia AT ruthmfredjimenez earlyonsetneutropeniainducedbyrituximabinapatientwithlupusnephritisandhemolyticanemia AT luismvila earlyonsetneutropeniainducedbyrituximabinapatientwithlupusnephritisandhemolyticanemia |
_version_ |
1725660374379790336 |